The paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trials - 04/12/23
Abstract |
The advent of chimeric antigen receptor T cells (CAR-T cells) has made a tremendous revolution in the era of cancer immunotherapy, so that since 2017 eight CAR-T cell products have been granted marketing authorization. All of these approved products are generated from autologous sources, but this strategy faces several challenges such as time-consuming and expensive manufacturing process and reduced anti-tumor potency of patients’ T cells due to the disease or previous therapies. The use of an allogeneic source can overcome these issues and provide an industrial, scalable, and standardized manufacturing process that reduces costs and provides faster treatment for patients. Nevertheless, for using allogeneic CAR-T cells, we are faced with the challenge of overcoming two formidable impediments: severe life-threatening graft-versus-host-disease (GvHD) caused by allogeneic CAR-T cells, and allorejection of allogeneic CAR-T cells by host immune cells which is called “host versus graft” (HvG). In this study, we reviewed recent registered clinical trials of allogeneic CAR-T cell therapy to analyze different approaches to achieve a safe and efficacious “off-the-shelf” source for chimeric antigen receptor (CAR) based immunotherapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Allogeneic CAR-T cell therapy faces two challenges: GvHD and HvG. |
• | The risk of GvHD can be reduced by blocking TCR expression/signaling. |
• | Elimination of MHC and enhanced lymphodepletion, are approaches to prevent HvG. |
Keywords : CAR (chimeric Antigen Receptor), GvHD, Allogeneic, Off-the-shelf, Clinical, Trials
Plan
Vol 169
Article 115888- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?